Anthony P Heaney

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi Pituitary tumour pathogenesis
    Anthony P Heaney
    Department of Medicine, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Br Med Bull 75:81-97. 2005
  2. ncbi PPAR-gamma in Cushing's disease
    Anthony P Heaney
    Division of Endocrinology, Cedars Sinai Research Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Pituitary 7:265-9. 2004
  3. ncbi Molecular targets in pituitary tumours
    Anthony P Heaney
    Cedars-Sinai Research Institute, 8700 Beverly Blvd, Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Nat Rev Cancer 4:285-95. 2004
  4. ncbi Novel pituitary ligands: peroxisome proliferator activating receptor-gamma
    Anthony P Heaney
    Division of Endocrinology, Cedars Sinai Research Institute, Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Pituitary 6:153-9. 2003
  5. ncbi PPAR-gamma receptor ligands: novel therapy for pituitary adenomas
    Anthony P Heaney
    Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    J Clin Invest 111:1381-8. 2003
  6. ncbi Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas
    Anthony P Heaney
    Department of Medicine, Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA
    Nat Med 8:1281-7. 2002
  7. ncbi Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells
    Anat Ben-Shlomo
    Division of Endocrinology and Metabolism, Cedars Sinai Research Institute, University of California School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 88:858-63. 2003
  8. ncbi Fructose induces transketolase flux to promote pancreatic cancer growth
    Haibo Liu
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90024, USA
    Cancer Res 70:6368-76. 2010
  9. ncbi Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression
    Gregory A Horwitz
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    Mol Endocrinol 17:600-9. 2003
  10. ncbi The alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappaB signalling to induce breast cancer cell apoptosis
    Hongxiang Hui
    Division of Endocrinology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90024, USA
    Eur J Cancer 44:160-6. 2008

Research Grants

  1. Chemoprevention of Pituitary Corticotroph Tumors
    Anthony Heaney; Fiscal Year: 2006
  2. Refined Fructose Promotes Pancreatic Cancer Growth
    Anthony Heaney; Fiscal Year: 2007
  3. ROSIALITAZONE: NOVEL THERAPY FOR PITUITARY TUMORS (PHAS*
    Anthony Heaney; Fiscal Year: 2007

Collaborators

Detail Information

Publications25

  1. ncbi Pituitary tumour pathogenesis
    Anthony P Heaney
    Department of Medicine, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Br Med Bull 75:81-97. 2005
    ..The interplay between genetic and humoural factors to promote cellular transformation is exemplified in pituitary tumorigenesis and is discussed in this review...
  2. ncbi PPAR-gamma in Cushing's disease
    Anthony P Heaney
    Division of Endocrinology, Cedars Sinai Research Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Pituitary 7:265-9. 2004
    ....
  3. ncbi Molecular targets in pituitary tumours
    Anthony P Heaney
    Cedars-Sinai Research Institute, 8700 Beverly Blvd, Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Nat Rev Cancer 4:285-95. 2004
  4. ncbi Novel pituitary ligands: peroxisome proliferator activating receptor-gamma
    Anthony P Heaney
    Division of Endocrinology, Cedars Sinai Research Institute, Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Pituitary 6:153-9. 2003
    ....
  5. ncbi PPAR-gamma receptor ligands: novel therapy for pituitary adenomas
    Anthony P Heaney
    Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    J Clin Invest 111:1381-8. 2003
    ..TZDs are proposed as novel oral medications for managing pituitary tumors...
  6. ncbi Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas
    Anthony P Heaney
    Department of Medicine, Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA
    Nat Med 8:1281-7. 2002
    ..Based on these findings, thiazolidinediones may be an effective therapy for Cushing disease..
  7. ncbi Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells
    Anat Ben-Shlomo
    Division of Endocrinology and Metabolism, Cedars Sinai Research Institute, University of California School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 88:858-63. 2003
    ..These observations indicate a role for LIF in loss of autocrine PRL suppression contributing to unrestrained prolactinomas PRL secretion. Moreover, PRL suppression by LIF may be mediated by gp130 and D2R interaction...
  8. ncbi Fructose induces transketolase flux to promote pancreatic cancer growth
    Haibo Liu
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90024, USA
    Cancer Res 70:6368-76. 2010
    ..They have major significance for cancer patients given dietary refined fructose consumption, and indicate that efforts to reduce refined fructose intake or inhibit fructose-mediated actions may disrupt cancer growth...
  9. ncbi Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression
    Gregory A Horwitz
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    Mol Endocrinol 17:600-9. 2003
    ..These results indicate that targeting PTTG1-mediated signaling alters the hormonal phenotype in pituitary cells and disrupted PTTG1 action may be a potential subcellular therapeutic tool for repressing PRL hypersecretion...
  10. ncbi The alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappaB signalling to induce breast cancer cell apoptosis
    Hongxiang Hui
    Division of Endocrinology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90024, USA
    Eur J Cancer 44:160-6. 2008
    ..Doxazosin is proposed as a possible novel medical therapy for breast cancer...
  11. ncbi Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas
    Manory A Fernando
    Division of Endocrinology, B-127, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Mol Endocrinol 19:3085-96. 2005
    ..dox is proposed as a possible novel medical therapy for pituitary tumors...
  12. ncbi Targeting pituitary tumors
    Anthony P Heaney
    Division of Endocrinology and Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, Calif, USA
    Horm Res 68:132-6. 2007
    ..Empiric exploration of novel targeted therapies developed for other tumor types, guided by pharmacogenomic profiling studies, will likely reveal the utility of many of these novel targeted agents in the treatment of pituitary tumors...
  13. ncbi Fructose impairs glucose-induced hepatic triglyceride synthesis
    Danshan Huang
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Lipids Health Dis 10:20. 2011
    ..These studies provide novel insight into the mechanisms involved in fructose-mediated hepatic hypertriglyceridemia and identify fructose-uptake as a new potential therapeutic target for lipid-associated diseases...
  14. ncbi Securin is overexpressed in breast cancer
    Selam Ogbagabriel
    Department of Medicine, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA, USA
    Mod Pathol 18:985-90. 2005
    ..We propose immunohistochemical tumor securin expression as a potential invasive marker, and novel therapeutic target in breast cancer...
  15. ncbi Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature
    Run Yu
    Division of Endocrinology, Cedars Sinai Medical Cente, Los Angeles, CA 90048, USA
    Pancreas 36:428-31. 2008
    ..Nesidioblastosis and hyperplasia of alpha cells should be considered in the differential diagnosis of hyperglucagonemia. Somatostatin analog may be used to suppress glucagon secretion in alpha-cell hyperplasia...
  16. ncbi Pituitary function in patients with normal pressure hydrocephalus before and after neurosurgical correction
    Tannaz Moin
    Department of Medicine, Veterans Affairs of Greater Los Angeles, David Geffen School of Medicine, University of California, Los Angeles, California 90073, USA
    J Clin Endocrinol Metab 97:3545-9. 2012
    ..We also sought to ascertain whether surgical correction of hydrocephalus would result in improvement of any noted pituitary dysfunction...
  17. ncbi Refined fructose and cancer
    Haibo Liu
    University of California, David Geffen School of Medicine, Division of Endocrinology, Departments of Medicine and Neurosurgery, Los Angeles, CA 90024, USA
    Expert Opin Ther Targets 15:1049-59. 2011
    ..Cancer cells utilize similar sugars in distinct ways, which may present important new therapeutic avenues of targeting cancer...
  18. ncbi Functional role of estrogen in pituitary tumor pathogenesis
    Anthony P Heaney
    Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA
    J Clin Invest 109:277-83. 2002
    ....
  19. ncbi Acromegaly due to an ectopic pituitary adenoma in the clivus: case report and review of literature
    Julia Goulart Appel
    Department of Medicine, David Geffen School of Medicine at UCLA, 9 240 N Factor Building, Los Angeles, CA 90095, USA
    Pituitary 15:S53-6. 2012
    ..The epidemiology and pertinent literature of this uncommon condition is discussed...
  20. ncbi Regulation of adipose differentiation by fructose and GluT5
    Li Du
    David Geffen School of Medicine, Division of Endocrinology, 9240 P Factor Building, Los Angeles, California 90095, USA
    Mol Endocrinol 26:1773-82. 2012
    ..Taken together, these results demonstrate that fructose and GluT5 play an important role in regulating adipose differentiation...
  21. ncbi Bilateral adrenalectomy: lifesaving procedure in severe Cushing syndrome
    Jennifer Y Han
    Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California 90095, USA
    Endocr Pract 18:e85-90. 2012
    ..To discuss the role of bilateral adrenalectomy in Cushing syndrome, as illustrated in a case of severe hypercortisolism that was unresponsive to combination agent medical therapy...
  22. ncbi Clinical review: Pituitary carcinoma: difficult diagnosis and treatment
    Anthony P Heaney
    Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095, USA
    J Clin Endocrinol Metab 96:3649-60. 2011
    ..Diagnosis is difficult, resulting in delays that may adversely effect outcome that is traditionally poor. Barriers to earlier diagnosis and management strategies for pituitary carcinoma are discussed...
  23. ncbi Direct spectrophotometric determination of serum fructose in pancreatic cancer patients
    Hongxiang Hui
    Division of Endocrinology, David Geffen School of Medicine at UCLA, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, CA 90024, USA
    Pancreas 38:706-12. 2009
    ..We sought to develop an assay to measure circulating fructose concentrations in pancreatic cancer patients...
  24. ncbi Temozolomide: a novel treatment for pituitary carcinoma
    Stephen Lim
    Department of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Lancet Oncol 7:518-20. 2006
  25. ncbi Pituitary tumour transforming gene in endocrine cancer
    Chris J McCabe
    Division of Medical Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK
    Clin Endocrinol (Oxf) 58:673-82. 2003

Research Grants3

  1. Chemoprevention of Pituitary Corticotroph Tumors
    Anthony Heaney; Fiscal Year: 2006
    ..Our ultimate goal is to develop a rationale for clinical application of these PPAR-gamma ligands as a novel medical therapy in Cushing's disease. ..
  2. Refined Fructose Promotes Pancreatic Cancer Growth
    Anthony Heaney; Fiscal Year: 2007
    ..Our identification of GLUT-5 as a key in the molecular mechanism by which pancreatic cancer cells preferentially utilize fructose may pave the way to novel therapeutic approaches targeting GLUT-5 action in pancreatic cancer. ..
  3. ROSIALITAZONE: NOVEL THERAPY FOR PITUITARY TUMORS (PHAS*
    Anthony Heaney; Fiscal Year: 2007
    ..A complete response will be defined as normalization of urinary cortisol levels in the Cushing's patients, and disappearance of pituitary tumors in the non-secreting tumors from baseline. ..